38 unknown. 38 Phase 3, 6 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 38 | Unknown 38 |
| Phase 2 | 6 | Unknown 6 |
Follow Multiple Myeloma: new trials by email Literature Review of Multiple Myeloma trials Research Report on Multiple Myeloma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of the Efficacy and Safety of Monotherapy With BCD-264 and Darzalex in Subjects With Relapsed and Refractory Multiple Myeloma BCD-264, Darzalex - Multiple Myeloma | Phase 3 | Unknown | Biocad | 252 | 2023-12-21 | 2024-03-06 |
| Lapelga vs Gastrofil Grastofil®, Lapelga - Multiple Myeloma, Lymphoma | Phase 3 | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 74 | 2023-11-01 | 2023-11-03 |
| CURATE.AI Optimized Modulation for Multiple Myeloma Bortezomib, Cyclophosphamide, Dexamethasone - Multiple Myeloma | Phase 2 / Phase 3 | Unknown | National University Hospital, Singapore | 20 | 2023-09-10 | 2023-09-06 |
| The Efficacy and Safety of Colchicine Combined With Conventional Therapy in Multiple Myeloma Patients Colchicine, Lenalidomide - Multiple Myeloma | Phase 3 | Unknown | Affiliated Hospital of Nantong University | 30 | 2022-03-30 | 2023-04-07 |
| Observation of the Efficacy of BAd Regimen in the Treatment of Relapsed and Refractory Multiple Myeloma Bendamustine - Bendamustine, Multiple Myeloma | Phase 3 | Unknown | Liao Aijun | 10 | 2021-06-01 | 2021-08-16 |
| A Study of the Efficacy and Safety of Pomalidomide Capsules Combined With Low-Dose Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma Pomalidomide, Dexamethasone - Multiple Myeloma, Recurrent or Refractory | Phase 3 | Unknown | Qilu Pharmaceutical Co., Ltd. | 85 | 2021-01-04 | 2022-02-11 |
| Myeloma XIV: Frailty-adjusted Therapy in Transplant Non-Eligible Patients With Newly Diagnosed Multiple Myeloma R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - reactive arm, R1: Ixazomib, Lenalidomide, Dexamethasone (IRD) induction therapy - adaptive arm, R2: Lenalidomide plus placebo maintenance - Multiple Myeloma | Phase 3 | Unknown | University of Leeds | 740 | 2020-08-04 | 2021-06-15 |
| Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma Rivaroxaban, ASA - Multiple Myeloma in Relapse, Multiple Myeloma Progression | Phase 2 / Phase 3 | Unknown | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 57 | 2019-01-17 | 2024-02-29 |
| Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation Cyclo Thal Dex Daratumumab - Multiple Myeloma Stage I | Phase 3 | Unknown | Grupo de Estudos Multicentricos em Onco-Hematologia | 20 | 2018-11-20 | 2019-01-03 |
| Mel vs BUCY+VP-16 Conditioning Regimen for MM Undergoing Auto-HSCT Busulfan (BU), Cyclophosphamide (CY), Etoposide (VP-16) - Autologous Hematopoietic Stem Cell Transplantation, Conditioning | Phase 2 / Phase 3 | Unknown | Nanfang Hospital, Southern Medical University | 122 | 2018-01-02 | 2020-02-25 |
| Study of BiRd Regimen Combined With BCMA CAR T-cell Therapy in Newly Diagnosed Multiple Myeloma (MM) Patients clarithromycin, lenalidomide, dexamethasone and autologous BCMA-directed CAR T-cells - Multiple Myeloma | Phase 3 | Unknown | The First Affiliated Hospital of Soochow University | 20 | 2017-10-19 | 2021-10-25 |
| Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma Pomalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Unknown | Jiangsu Simcere Pharmaceutical Co., Ltd. | 73 | 2016-09-01 | 2016-11-02 |
| GEM-CLARIDEX: Ld vs BiRd Clarithromycin, Lenalidomide, Dexamethasone - Multiple Myeloma | Phase 3 | Unknown | PETHEMA Foundation | 286 | 2015-09-01 | 2022-02-01 |
| CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma Cyclophosphamide, Bortezomib, Dexamethasone - Multiple Myeloma | Phase 3 | Unknown | Sun Yat-sen University | 236 | 2015-04-01 | 2016-04-20 |
| MSC and Cyclophosphamide for Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis Cyclophosphamide, Mesenchymal stromal cells - Leukemia, Multiple Myeloma | Phase 2 / Phase 3 | Unknown | National Research Center for Hematology, Russia | 40 | 2014-01-01 | 2014-10-21 |
| Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance Lenalidomide, Bortezomib, autologous stem cell transplant, allogeneic stem cell transplant - Previously Untreated Symptomatic Multiple Myeloma | Phase 3 | Unknown | Wuerzburg University Hospital | 406 | 2012-05-01 | 2023-04-27 |
| Clarithromycin Plus CTd Regimen for Patients With Newly Diagnosed Multiple Myeloma Clarithromycin, Thalidomide, Cyclophosphamide - Multiple Myeloma | Phase 3 | Unknown | Jinling Hospital, China | 130 | 2012-04-01 | 2017-09-06 |
| Comparable Investigation of One Fraction Radiotherapy and Multifraction Radiotherapy in Patients With Multiple Myeloma. External Beam radiotherapy - Multiple Myeloma and Malignant Plasma Cell Neoplasms | Phase 3 | Unknown | Lithuanian University of Health Sciences | 100 | 2011-09-01 | 2013-12-31 |
| Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen, Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen, Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen - Multiple Myeloma | Phase 3 | Unknown | University of Leeds | 4420 | 2010-05-01 | 2018-06-11 |
| Autologous Bone Marrow Transplantation (BMT) Compared With Allogeneic BMT in Multiple Myeloma Autologous bone marrow transplantation, Allogeneic bone marrow transplantation - Multiple Myeloma | Phase 2 / Phase 3 | Unknown | Tehran University of Medical Sciences | 185 | 2009-10-01 | 2012-06-04 |
Showing 20 of 38. Sign in to see all of them.
Neoplasms, Plasma Cell (9) · Leukemia (4) · Lymphoma (4) · Leukemia, Lymphocytic, Chronic, B-Cell (3) · Lymphoma, B-Cell, Marginal Zone (3) · Lymphoma, Follicular (3) · Lymphoma, Non-Hodgkin (3) · Burkitt Lymphoma (2) · Hodgkin Disease (2) · Leukemia, Myeloid, Acute (2) · Lymphoma, Large B-Cell, Diffuse (2) · Lymphoma, Large-Cell, Immunoblastic (2) · Lymphoma, Mantle-Cell (2) · Peripheral Nervous System Diseases (2)
Blood Protein Disorders (38) · Cardiovascular Diseases (38) · Hemic and Lymphatic Diseases (38) · Hemorrhagic Disorders (38) · Hemostatic Disorders (38) · Immune System Diseases (38) · Immunoproliferative Disorders (38) · Lymphoproliferative Disorders (38) · Neoplasms by Histologic Type (38) · Paraproteinemias (38) · Vascular Diseases (38) · Hematologic Diseases (37) · Neoplasms (37) · Neoplasms, Plasma Cell (29) · Pathological Conditions, Signs and Symptoms (7)
Dexamethasone (15) · Cyclophosphamide (13) · Melphalan (9) · Lenalidomide (7) · Thalidomide (6) · Bortezomib (5) · Doxorubicin (5) · Prednisone (4) · Clarithromycin (3) · Filgrastim (3) · Busulfan (2) · Carmustine (2) · Idarubicin (2) · Interferon-alpha (2) · Radiotherapy (2)
Grupo de Estudos Multicentricos em Onco-Hematologia (2) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (2) · Medical Research Council (2) · University of Leeds (2) · Affiliated Hospital of Nantong University (1) · Azienda Ospedaliera San Giovanni Battista (1) · Biocad (1) · Charite University, Berlin, Germany (1) · Commissie Voor Klinisch Toegepast Onderzoek (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Heidelberg University (1) · Intergroupe Francophone du Myelome (1) · Jiangsu Simcere Pharmaceutical Co., Ltd. (1) · Jinling Hospital, China (1) · Leeds Cancer Centre at St. James's University Hospital (1)
China (8) · United Kingdom (8) · Germany (5) · Belgium (3) · Italy (3) · Brazil (2) · France (2) · Netherlands (2) · Russia (2) · Austria (1) · Canada (1) · Iran (1) · Israel (1) · Lithuania (1) · Singapore (1)
Aili He, MD, PhD (1) · Ardeshir Ghavamzadeh, MD (1) · Baijun Fang, MD, PhD (1) · Barry J.A. Laird, MD (1) · Benedetto Bruno, MD, PhD (1) · Binghua Wang, MD, PhD (1) · Congmeng Lin, MD, PhD (1) · Da Gao, MD, PhD (1) · Diana Samson, MD (1) · Eliezer Rachmilewitz, MD (1) · Fernando Dimeo, MD (1) · Gerlinde Egerer, MD (1) · Gordon Cook, MD (1) · Gordon Cook, MD, PhD (1) · Graham Jackson (1)
PMID 11137554, PMID 15189396, PMID 15842354, PMID 17360989, PMID 18094721, PMID 18166796, PMID 19880501, PMID 20637084, PMID 21146205, PMID 21410373, PMID 21849487, PMID 22058209, PMID 22409262, PMID 22442350, PMID 22498745, PMID 23298856, PMID 23721099, PMID 23897961, PMID 23903204, PMID 24948586, PMID 25225424, PMID 25439696, PMID 25878332, PMID 26137203, PMID 26282654, PMID 26452191, PMID 26778538, PMID 26827659, PMID 26986753, PMID 27374467, PMID 27829371, PMID 33006656, PMID 33151787, PMID 33242443, PMID 34021118, PMID 34582035, PMID 35377708, PMID 35654466, PMID 35790108, PMID 36315921, PMID 38112795, PMID 38195983, PMID 40575076, PMID 40834881, PMID 41832666, PMID 6966400, PMID 7520771
2005 (1), 2009 (1), 2015 (1)